Skip to main content
  • ASM
    • Antimicrobial Agents and Chemotherapy
    • Applied and Environmental Microbiology
    • Clinical Microbiology Reviews
    • Clinical and Vaccine Immunology
    • EcoSal Plus
    • Infection and Immunity
    • Journal of Bacteriology
    • Journal of Clinical Microbiology
    • Journal of Microbiology & Biology Education
    • Journal of Virology
    • mBio
    • Microbiology and Molecular Biology Reviews
    • Microbiology Resource Announcements
    • Microbiology Spectrum
    • Molecular and Cellular Biology
    • mSphere
    • mSystems
  • Log in
  • My alerts
  • My Cart

Main menu

  • Home
  • Articles
    • Current Issue
    • Accepted Manuscripts
    • COVID-19 Special Collection
    • Minireviews
    • JVI Classic Spotlights
    • Archive
  • For Authors
    • Submit a Manuscript
    • Scope
    • Editorial Policy
    • Submission, Review, & Publication Processes
    • Organization and Format
    • Errata, Author Corrections, Retractions
    • Illustrations and Tables
    • Nomenclature
    • Abbreviations and Conventions
    • Publication Fees
    • Ethics Resources and Policies
  • About the Journal
    • About JVI
    • Editor in Chief
    • Editorial Board
    • For Reviewers
    • For the Media
    • For Librarians
    • For Advertisers
    • Alerts
    • RSS
    • FAQ
  • Subscribe
    • Members
    • Institutions
  • ASM
    • Antimicrobial Agents and Chemotherapy
    • Applied and Environmental Microbiology
    • Clinical Microbiology Reviews
    • Clinical and Vaccine Immunology
    • EcoSal Plus
    • Infection and Immunity
    • Journal of Bacteriology
    • Journal of Clinical Microbiology
    • Journal of Microbiology & Biology Education
    • Journal of Virology
    • mBio
    • Microbiology and Molecular Biology Reviews
    • Microbiology Resource Announcements
    • Microbiology Spectrum
    • Molecular and Cellular Biology
    • mSphere
    • mSystems

User menu

  • Log in
  • My alerts
  • My Cart

Search

  • Advanced search
Journal of Virology
publisher-logosite-logo

Advanced Search

  • Home
  • Articles
    • Current Issue
    • Accepted Manuscripts
    • COVID-19 Special Collection
    • Minireviews
    • JVI Classic Spotlights
    • Archive
  • For Authors
    • Submit a Manuscript
    • Scope
    • Editorial Policy
    • Submission, Review, & Publication Processes
    • Organization and Format
    • Errata, Author Corrections, Retractions
    • Illustrations and Tables
    • Nomenclature
    • Abbreviations and Conventions
    • Publication Fees
    • Ethics Resources and Policies
  • About the Journal
    • About JVI
    • Editor in Chief
    • Editorial Board
    • For Reviewers
    • For the Media
    • For Librarians
    • For Advertisers
    • Alerts
    • RSS
    • FAQ
  • Subscribe
    • Members
    • Institutions
Transformation and Oncogenesis

Repression of the Integrated Papillomavirus E6/E7 Promoter Is Required for Growth Suppression of Cervical Cancer Cells

Delicia A. Francis, Susanne I. Schmid, Peter M. Howley
Delicia A. Francis
Department of Pathology, Harvard Medical School, Boston, Massachusetts 02115
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Susanne I. Schmid
Department of Pathology, Harvard Medical School, Boston, Massachusetts 02115
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Peter M. Howley
Department of Pathology, Harvard Medical School, Boston, Massachusetts 02115
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
DOI: 10.1128/JVI.74.6.2679-2686.2000
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

Article Figures & Data

Figures

  • Tables
    • Open in new tab
    • Download powerpoint
    • Open in new tab
    • Download powerpoint
    Fig. 1.

    HPV16 and E6 and E7 expression levels in HeLa cell subclones. (A) Total RNA was isolated from confluent plates of each indicated HeLa clone. Ten micrograms of total RNA was subjected to electrophoresis in a 1.2% formaldehyde gel, transferred to a positively charged nylon membrane (Amersham), and hybridized with a32P-radiolabeled probe specific for HPV16 E6/E7 mRNA (Top). Hybridization with a GAPDH probe was used to normalize the data for loading variability (bottom). (B) The relative levels of HPV16 E6/E7 mRNA were quantitated using a densitometer (Molecular Dynamics) and normalized against the GAPDH RNA levels. The relative levels of normalized mRNA relative to SiHa HPV16 mRNA levels were graphed. RNA from HPV18-positive HeLa cells was used as the negative control. RNA from the HPV16-positive SiHa cell line was used as a positive control. HPV16 and HPV18 probes do not cross-hybridize under the stringent annealing and washing conditions used.

  • Fig. 2.
    • Open in new tab
    • Download powerpoint
    Fig. 2.

    HPV16 E7 protein levels in HeLa cell subclones. Whole-cell lysates from HPV16 E6- and E7-expressing clones were resolved by SDS-PAGE and then analyzed by immunoblotting with monoclonal antibody 8c9, specific for HPV16 E7, as indicated (top). Extracts from normal HeLa cells were used as a negative control. As positive controls, whole-cell extracts from rat kidney fibroblasts cells constitutively expressing HPV16 E7 (RKO-7.2) (27), as well as from the HPV16-positive cell line SiHa, were used. To control for protein loading, the blot was also probed with an antibody specific for actin (bottom).

  • Fig. 3.
    • Open in new tab
    • Download powerpoint
    Fig. 3.

    Colony reduction assay. Normal HeLa cells, retroviral LXSN vector cells, and HPV16 E6- and E7-expressing HeLa cell clones 1, 2, 16, and 17 were maintained in DMEM supplemented with 10% fetal bovine serum. Cells were seeded into six-well dishes at densities that resulted in approximately 50% confluence after 24 h. As described in Materials and Methods, cells were transfected with 1 μg of pBabe-puro along with 9 μg of vector or the E2TA or E2TR plasmid using Fugene (Boehringer Mannheim). After 21 days, the remaining cells were fixed and stained with methylene blue and the colonies were counted. The averaged total numbers of colonies from three independent experiments are shown. E2TA, full-length BPV-1 E2 protein; E2TR, BPV-1 E2 variant lacking the N terminus transactivation domain; vector, empty expression plasmid.

  • Fig. 4.
    • Open in new tab
    • Download powerpoint
    Fig. 4.

    Dose response of transient HPV16 E6 and E7 expression on E2-mediated growth arrest. HeLa cells were cotransfected with 6 μg of empty vector or the E2TA plasmid along with increasing concentrations of HPV16 E6/E7 plasmid as indicated. After 21 days, the total number of puromycin-resistant colonies was determined as described in the legend to Fig. 3. Results shown are representative of a single experiment.

  • Fig. 5.
    • Open in new tab
    • Download powerpoint
    Fig. 5.

    Northern blot analysis of HPV18 E6/E7 mRNA levels. Cytoplasmic total RNA was isolated from the indicated cell lines transfected with empty vector (vector) or the E2TA or E2TR plasmid and electrophoresed on a 1.2% agarose gel containing formaldehyde. The membrane was hybridized with a 32P-radiolabeled probe specific for HPV18 E6/E7 (A), HPV16 E6/E7 (B), or GAPDH (C) mRNA.

  • Fig. 6.
    • Open in new tab
    • Download powerpoint
    Fig. 6.

    E2TR inhibition of reporter gene transcription in HeLa cells. HeLa cells were cotransfected with 20 ng of the E2TA plasmid, 1 μg of a luciferase reporter plasmid containing four E2-binding sites, and increasing amounts of the E2TR plasmid. Cellular extracts were prepared at 48 h posttransfection, and luciferase activity was measured. The basal activity of the luciferase reporter plasmid in the absence of E2TA was 391. The graphed results are the averages of three independent experiments.

Tables

  • Figures
  • Table 1.

    Colony reduction assaya

    Cell lineHPV DNA statusbStatus of gene forc:No. of puromycin-resistant colonies after transfection with:
    pRbp53VectorE2TA plasmidE2TR plasmid
    HeLa+wtwt74070762
    SiHa+wtwt11110117
    C33A−mutmut1,4241,4861,392
    U20S−wtwt564552452
    • ↵a The indicated cell lines were transfected with vector alone or E2TA or E2TR plasmids, along with pBabe-puro. Twenty-four hours after transfection, cell cultures were divided between two 10-cm-diameter plates, allowed to attach, and placed under selection in media containing 0.7 μg of the selection antibiotic/ml. The number of drug-resistant colonies was determined after 3 weeks.

    • ↵b +, positive; −, negative.

    • ↵c wt, wild type; mut, mutant.

PreviousNext
Back to top
Download PDF
Citation Tools
Repression of the Integrated Papillomavirus E6/E7 Promoter Is Required for Growth Suppression of Cervical Cancer Cells
Delicia A. Francis, Susanne I. Schmid, Peter M. Howley
Journal of Virology Mar 2000, 74 (6) 2679-2686; DOI: 10.1128/JVI.74.6.2679-2686.2000

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Print

Alerts
Sign In to Email Alerts with your Email Address
Email

Thank you for sharing this Journal of Virology article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Repression of the Integrated Papillomavirus E6/E7 Promoter Is Required for Growth Suppression of Cervical Cancer Cells
(Your Name) has forwarded a page to you from Journal of Virology
(Your Name) thought you would be interested in this article in Journal of Virology.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
Repression of the Integrated Papillomavirus E6/E7 Promoter Is Required for Growth Suppression of Cervical Cancer Cells
Delicia A. Francis, Susanne I. Schmid, Peter M. Howley
Journal of Virology Mar 2000, 74 (6) 2679-2686; DOI: 10.1128/JVI.74.6.2679-2686.2000
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Top
  • Article
    • ABSTRACT
    • MATERIALS AND METHODS
    • RESULTS
    • DISCUSSION
    • ACKNOWLEDGMENTS
    • FOOTNOTES
    • REFERENCES
  • Figures & Data
  • Info & Metrics
  • PDF

KEYWORDS

Gene Expression Regulation, Viral
Oncogene Proteins, Viral
Papillomaviridae
Promoter Regions, Genetic
Repressor Proteins
Uterine Cervical Neoplasms
virus integration

Related Articles

Cited By...

About

  • About JVI
  • Editor in Chief
  • Editorial Board
  • Policies
  • For Reviewers
  • For the Media
  • For Librarians
  • For Advertisers
  • Alerts
  • RSS
  • FAQ
  • Permissions
  • Journal Announcements

Authors

  • ASM Author Center
  • Submit a Manuscript
  • Article Types
  • Ethics
  • Contact Us

Follow #Jvirology

@ASMicrobiology

       

 

JVI in collaboration with

American Society for Virology

ASM Journals

ASM journals are the most prominent publications in the field, delivering up-to-date and authoritative coverage of both basic and clinical microbiology.

About ASM | Contact Us | Press Room

 

ASM is a member of

Scientific Society Publisher Alliance

 

American Society for Microbiology
1752 N St. NW
Washington, DC 20036
Phone: (202) 737-3600

Copyright © 2021 American Society for Microbiology | Privacy Policy | Website feedback

Print ISSN: 0022-538X; Online ISSN: 1098-5514